Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Eidos Therapeutics Inc (EIDX) USD0.001

Sell:$44.73 Buy:$44.92 Change: $0.18 (0.40%)
NASDAQ:0.13%
Market closed |  Prices as at close on 11 November 2019 | Switch to live prices |
Sell:$44.73
Buy:$44.92
Change: $0.18 (0.40%)
Market closed |  Prices as at close on 11 November 2019 | Switch to live prices |
Sell:$44.73
Buy:$44.92
Change: $0.18 (0.40%)
Market closed |  Prices as at close on 11 November 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on addressing the unmet need in diseases caused by transthyretin (TTR), amyloidosis (ATTR). It focuses on treating the disease by targeting them at their collective source by stabilizing TTR. The Company’s product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. AG10 binds and stabilizes TTR in the blood, preventing the formation of amyloid and halting progression of the disease.

Contact details

Address:
101 Montgomery St Ste 2550
SAN FRANCISCO
94104-4158
United States
Telephone:
+1 (650) 3919740
Website:
eidostx.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EIDX
ISIN:
US28249H1041
Market cap:
$1.69 billion
Shares in issue:
37.50 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Jonathan Fox
    President, chief medical officer
  • Neil Kumar
    Chief Executive Officer, Director
  • Christine Siu
    Chief Financial Officer, Principal Accounting Officer
  • Uma Sinha
    Chief Scientific Officer
  • Cameron Turtle
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.